JG
CYTK icon

Joel Greenblatt’s Cytokinetics CYTK Stock Holding History

Joel Greenblatt’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Buy
+5,367
New +$385K ﹤0.01% 1537
2017
Q3 		– Sell
-16,860
Closed -$204K – 932
2017
Q2 		$204K Sell
16,860
-33,047
-66% -$459K ﹤0.01% 902
2017
Q1 		$641K Buy
+49,907
New +$583K 0.01% 730

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Joel Greenblatt's CYTK Position: Q2 2026 in Review

Joel Greenblatt opened a new position in Cytokinetics (CYTK) in Q2 2026: 5,367 shares worth $457K. The stake represents ﹤0.01% of the portfolio and ranks #1537 among its holdings. This is a return to the name: Joel Greenblatt previously reported a position in CYTK as recently as Q2 2017.

Joel Greenblatt first reported a position in CYTK in Q1 2017 and has held it in 3 quarters since. The position peaked at $641K in Q1 2017. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Joel Greenblatt held 5,367 shares of Cytokinetics worth $457K as of Q2 2026.
  • Cytokinetics was a new Joel Greenblatt position in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1537 holding.
  • Joel Greenblatt first reported a position in Cytokinetics in Q1 2017 and has held it in 3 quarters since.
  • Joel Greenblatt's Cytokinetics position peaked at $641K in Q1 2017.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.